Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis
1.Department of Neuroscience DNS, School of Medicine, University of Padua, Via Giustiniani, 5, 35128, Padua, Veneto Region, Italy ;2.Multiple Sclerosis Centre, University Hospital of Padua, Padua, Veneto Region, Italy ;
Abstract:
Journal of Neurology - Ocrelizumab was found to decrease brain atrophy rate in primary progressive multiple sclerosis (PPMS), but no data are currently available on the effect of ocrelizumab on...